Q3 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Home / Stocks / Senti Biosciences Holdings I
Institutional Holders · Q3 2026

Who owns Senti Biosciences Holdings I?

SNTICUSIP 816944102
22
Institutions holding · +15.8% QoQ
$387,402
Aggregate reported value · −82.4%
1.3M
Shares held (SH)
Top 22
The holders

Senti Biosciences Holdings I (SNTI) was held by 22 institutions as of Q3 2026, with a combined reported value of $387,402 (−82.4% from the previous quarter). The largest holder was Vanguard Capital Management Llc, reporting $167,701 — 43.3% of the total. The ten largest holders together account for 96.1% of the reported value.

Thirteen quarters of conviction

Aggregate reported value (bars) against the number of institutions holding (line).
Q2 26Q3 26

The holders

Top 22 of 22 institutions, ranked by reported value. Share change is versus the manager’s previous filing.
#ManagerSharesShare Δ QoQValue% of book
1Vanguard Capital Management Llc537,504+0.0%$167,7010.0%
2Geode Capital Management, Llc176,602−5.6%$55,1360.0%
3Two Sigma Securities, Llc153,480—$47,9160.0%
4Gts Securities Llc110,000—$34,3200.0%
5Vanguard Fiduciary Trust Co91,193+0.0%$28,4520.0%
6Menlo Ventures Management, L.P.35,737+0.0%$11,1570.0%
7Northern Trust Corp32,154+0.0%$10,0380.0%
8Susquehanna International Group, Llp23,147—$7,2260.0%
9UBS Group AG17,402+20.6%$5,4300.0%
10Citadel Advisors Llc16,365−84.7%$5,1090.0%
11XTX Topco Ltd14,885−37.0%$4,6470.0%
12State Street Corp10,010+0.0%$3,1250.0%
13Nuveen, LLC9,819—$3,0190.0%
14Tower Research Capital LLC (TRC)8,959+22.0%$2,7970.0%
15Royal Bank Of Canada4,015+0.0%$1,0000.0%
16SBI Securities Co., Ltd.523+56.6%$1630.0%
17BlackRock, Inc.262−93.5%$820.0%
18Morgan Stanley160−5.3%$500.0%
19Hrt Financial Lp53,827—$160.0%
20Virtu Financial LLC47,271+107.4%$150.0%
21Barclays Plc10−98.7%$30.0%
22Caitong International Asset Management Co., Ltd1+0.0%$00.0%
Source: Form 13F filings via SEC EDGAR. Positions as of Sep 30, 2026. Options (put/call) are excluded from share counts.

Major holders — Schedule 13D/G

Beneficial-ownership filings under Schedule 13D/G; the latest filing per holder is shown. Shares and percentages are as stated on the filing cover — a dash means the cover did not state the figure. Coverage: filings dated Jan 2, 2024 to Nov 18, 2026; this index is still being built and is updated daily.
FilerFormShares owned% of classEvent dateFiledFiling
New Enterprise Associates 15, L.P.SC 13D/A442,6159.6%2024-12-022024-12-04EDGAR ↗
Nantahala Capital Management, LLCSC 13G/A2,220,0008.1%2025-03-312025-05-15EDGAR ↗
Armistice Capital, LlcSC 13G/A1,439,8125.0%2025-03-312025-05-15EDGAR ↗
Nantahala Capital Partners Limited PartnershipSC 13G/A502,5001.9%2025-03-312025-05-15EDGAR ↗

Insider transactions — Form 4

Transactions reported on Form 4 (non-derivative positions). Coverage: filings dated Jan 2, 2025 to Apr 21, 2025; this index is still being built and is updated daily.
InsiderRoleDateTransactionSharesPriceShares afterFiling
Celadon Partners SPV 2410% owner2025-03-10C · Conversion+9,777,000—9,777,000EDGAR ↗
New Enterprise Associates 15, L.P.Other2025-03-10C · Conversion+3,333,000—3,775,615EDGAR ↗
Bayer Healthcare Llc10% owner2025-03-10C · Conversion+2,222,000—2,809,848EDGAR ↗
Rajangam KanyaPres. & Chief Med. & Dev. Off.2025-03-10C · Conversion+33,000$2.2533,000EDGAR ↗
Lu Timothy KCEO and Interim PFO and PAO2025-03-07A · Grant / award+642,358$0.00724,440EDGAR ↗
Rajangam KanyaPres. & Chief Med. & Dev. Off.2025-03-07A · Grant / award+78,363$0.0086,984EDGAR ↗
Rajangam KanyaPres. & Chief Med. & Dev. Off.2025-02-06S · Open-market sale−182$4.378,621EDGAR ↗
Lu Timothy KCEO2025-02-06S · Open-market sale−545$4.3682,082EDGAR ↗
Rajangam KanyaPres. & Chief Med. & Dev. Off.2025-02-04S · Open-market sale−1,297$4.078,803EDGAR ↗
Lu Timothy KCEO2025-02-04S · Open-market sale−3,922$4.0782,627EDGAR ↗